Clinical Research Directory
Browse clinical research sites, groups, and studies.
Genetics of the Acute Response to Oral Semaglutide
Sponsor: Medical University of Bialystok
Summary
The study aims to investigate the genetic basis of the response to short-term (3 months) orally administered semaglutide treatment, in terms of improving metabolic parameters, including the hormonal response to a standardized meal, and changes in body composition and liver steatosis. In the study, parameters such as fasting and 2-hour glucose during OGTT, HbA1c, body fat mass, body weight, total cholesterol, HDL and LDL, triglycerides, HOMA-IR, Matsuda Index and liver steatosis will be assessed. All the patients will undergo genome-wide genotyping. Moreover, in a subset of participants, muscle and fat biopsies will be performed, before and after the treatment, and liver, muscle and pancreas fat content will be assessed using MRI.
Official title: Genetics of the Acute Response to Oral Semaglutide (GAROS)
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
1000
Start Date
2022-09-01
Completion Date
2025-12-31
Last Updated
2025-03-26
Healthy Volunteers
Yes
Conditions
Interventions
Semaglutide Pill
Oral semaglutide treatment
Locations (1)
Clinical Research Centre, Medical University of Bialystok
Bialystok, Podlaskie Voivodeship, Poland